Hammerson PLC
20 December 2000
Hammerson Acquires City Development Opportunity
Hammerson has acquired a two thirds interest in Spitalfields Development
Group ('SDG') for a total of £18 million by acquiring the one third interests
previously owned by SPP and Metacorp. The remaining one third interest in SDG
is owned and will be retained by Balfour Beatty.
SDG's principal asset is a long leasehold interest in a development site, 10
Bishops Square, London, E1, which has potential for an office and retail
development of 18,580 sq m (200,000 sq ft). The freehold interest in the site
is owned by The Corporation of London. In addition, SDG has an interest in
the adjoining development site at 1 Bishops Square, the freehold of which is
also owned by The Corporation of London. SDG's interests have been combined
with those of The Corporation in a conditional joint venture which gives SDG
an effective 32% interest in the two proposed developments totalling 63,170
sq m (680,000 sq ft). Mike Bear will continue as Chief Executive of SDG.
John Richards, Chief Executive of Hammerson, said:
'This is an excellent location, close to Liverpool Street and Broadgate.
Hammerson's recent letting of its adjacent 280 Bishopsgate, part of
Spitalfields, underlines the buoyant demand for high quality office
accommodation in this area. We have successfully worked with Balfour Beatty
on a number of projects in the past and look forward to continuing this
relationship.'
Judith Mayhew, Chairman of The Policy and Resources Committee, The
Corporation of London, commented:
'The current strong demand for high quality office buildings is evidence of
the City of London's continuing role as Europe's financial capital and the
world's leading international financial and business centre. We welcome
Hammerson's involvement in this project together with Balfour Beatty, which
will help meet the demand for large business space users in the City of
London and regenerate this area of Spitalfields, creating more local
employment within Tower Hamlets.'
Peter Zinkin, Development Director of Balfour Beatty, said:
'The Spitalfields Development is a project that we have been working on for
many years and, as we move towards completing the development, we are very
pleased that Hammerson has entered this partnership.'
Hammerson was advised by Strutt & Parker. The letting agents for the proposed
developments are CB Hillier Parker. SPP were advised by Celexa REIM Ltd on
the disposal of their interest.
For further information:
John Richards
Chief Executive, Hammerson plc Tel: 020 7887 1000
Christopher Smith
Director of Corporate Affairs, Hammerson plc Tel: 020 7887 1000
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.